{"id":"brii-196-brii-198","safety":{"commonSideEffects":[{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Hypersensitivity reactions"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"BRII-196 and BRII-198 are individually engineered monoclonal antibodies designed to bind non-overlapping epitopes on the SARS-CoV-2 spike protein receptor-binding domain, preventing viral attachment to human ACE2 receptors. The combination approach is intended to reduce the risk of viral escape and resistance. This dual-antibody cocktail can be used for both post-exposure prophylaxis and early treatment of COVID-19.","oneSentence":"BRII-196/BRII-198 is a combination of two monoclonal antibodies that neutralize SARS-CoV-2 spike protein to prevent and treat COVID-19 infection.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:42:25.262Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Post-exposure prophylaxis of COVID-19"},{"name":"Early treatment of mild-to-moderate COVID-19"}]},"trialDetails":[{"nctId":"NCT04518410","phase":"PHASE2, PHASE3","title":"ACTIV-2: A Study for Outpatients With COVID-19","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-08-19","conditions":"Coronavirus, Covid19","enrollment":4044},{"nctId":"NCT05780424","phase":"PHASE3","title":"BRII-196/BRII-198 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-12-16","conditions":"COVID-19","enrollment":353},{"nctId":"NCT04501978","phase":"PHASE3","title":"ACTIV-3: Therapeutics for Inpatients With COVID-19","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-08-04","conditions":"Covid19","enrollment":2753},{"nctId":"NCT04952402","phase":"PHASE4","title":"SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-07-09","conditions":"Covid19, SARS-CoV2 Infection","enrollment":43},{"nctId":"NCT04691180","phase":"PHASE1","title":"A Phase 1 Study of Human Monoclonal Antibodies, BRII-196 and BRII-198","status":"COMPLETED","sponsor":"Brii Biosciences Limited","startDate":"2021-01-05","conditions":"COVID-19","enrollment":12},{"nctId":"NCT04770467","phase":"PHASE2","title":"A Safety and Efficacy Study of Human Monoclonal Antibodies, BRII-196 and BRII-198 for the Treatment of Patients With COVID-19","status":"WITHDRAWN","sponsor":"Brii Biosciences, Inc.","startDate":"2021-02","conditions":"COVID-19","enrollment":""},{"nctId":"NCT04787211","phase":"PHASE2","title":"A Study of Human Monoclonal Antibodies, BRII-196 and BRII-198","status":"COMPLETED","sponsor":"Brii Biosciences Limited","startDate":"2021-06-20","conditions":"COVID-19","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"BRII-196/BRII-198","genericName":"BRII-196/BRII-198","companyName":"National Institute of Allergy and Infectious Diseases (NIAID)","companyId":"national-institute-of-allergy-and-infectious-diseases-niaid","modality":"Biologic","firstApprovalDate":"","aiSummary":"BRII-196/BRII-198 is a combination of two monoclonal antibodies that neutralize SARS-CoV-2 spike protein to prevent and treat COVID-19 infection. Used for Post-exposure prophylaxis of COVID-19, Early treatment of mild-to-moderate COVID-19.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}